ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2279

Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort
Abstract Number: 0935

Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling
Abstract Number: 1579

Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
Abstract Number: 0251

Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Abstract Number: 1185

Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients
Abstract Number: 2372

Soluble Triggering Receptor Expressed on Myeloid Cell-1 Reflects the Cross-sectional Activity of Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Abstract Number: 0049

Soluble Uric Acid Is an Endogenous Inhibitor of CD38
Abstract Number: 1888

Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy
Abstract Number: 0813

Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Abstract Number: 2341

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 2366

Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Abstract Number: 1661

Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Abstract Number: 0911

Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations
Abstract Number: 2602

Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Abstract Number: 0038

Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].